Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Credit: AI-generated image

Text

Updated Nov 17, 2026 | 08:46 AM IST

SummaryThe European Commission granted marketing authorisation to Revolution Medicines to produce and sell RASONQUE (daraxonrasib) to treat aggressive metastatic pancreatic adenocarcinoma.

End of Article